Some biosimilars are approved for treating ulcerative colitis (UC). Learn how these medications can fit into your ulcerative colitis management.

September 28, 2012 — The US Food and Drug Administration (FDA) today approved adalimumab (Humira, Abbott Laboratories) for its seventh use: treating ulcerative colitis. Adalimumab is now ...

Persistence rates with the initial adalimumab biosimilar were 68.6% at 6 months and 60.4% at 12 months, and the overall survival without the discontinuation of the adalimumab biosimilars was 76.7% ...

A total of 231 participants receiving adalimumab with methotrexate and 1553 receiving adalimumab monotherapy were included in the cohort. 1 At 1 year, drug survival was 79.1% (95% CI, 71.8% to 87. ...

During the controlled portions of 39 global adalimumab clinical trials in adult patients with RA, PsA, AS, CD, UC, PS, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, 1.09 ...

At baseline, 79% of participants had elevated CRP (average 1.23 mg/dL), and 21% had normal CRP. Mean BMI in those respective groups was 34.1 versus 28.6 (P <0.001). About half of patients were ...

Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has designated the HADLIMA™ (adalimumab-bwwd) high- and low-concentration ...